Roche will be the first to join Harvard's Enterprise Research Campus in Allston, taking a suite in the first phase of the ...

Basel, 5 March 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has ...

Roche announced that it has struck an exclusive deal with Denmark's Zealand Pharma to develop and market petrelintide, a new treatment for obesity.

Roche and its Genentech subsidiary are planning to hitch up their cardiovascular, renal and metabolism R&D work and shift it over to a new center in Harvard’s Enterprise Research Campus. | Roche and ...

Pharmaceutical giant Roche announces opening of an innovation centre at Harvard University's corporate research campus.

Gazyva/Gazyvaro is an anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a CRR benefit in lupus ...

The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and Metabolism, as well as for data science and AI specialists to drive innovation in d ...

Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a complete renal response benefit1 The filing application is based on data from the phase ...

Our AVENIO assays offer robust solutions for oncology, including the recent approval of the AVENIO Tumor Tissue CGP Automated Kit, a collaboration between Roche and Foundation Medicine, two leaders in ...

Today, Roche is headquartered in Basel, Switzerland. The company now employs 80,000 people across a number of pharmaceutical and diagnostic sites across the world. The first of many successes ...

Swiss companies. Large corporates are not dependent on the domestic market. However, it could become more important for ...